Eli Lilly is paying up to $630m for a Phase I metabolic-associated steatohepatitis (MASH) candidate from South Korea-based biotech OliX Pharmaceuticals, diversifying its pipeline for the disease ...

a South Korean based biotechnology company focuses on developing innovative first-in-class drugs for treatment for metabolic dysfunction-associated steatohepatitis (MASH). MASH is a leading cause ...

a South Korean based biotechnology company focuses on developing innovative first-in-class drugs for treatment for metabolic dysfunction-associated steatohepatitis (MASH). MASH is a leading cause ...

SEONGNAM, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals ... a Phase 1 candidate primarily targeting metabolic-associated steatohepatitis (MASH) and other cardiometabolic indications.